Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers

Jordana E Hoppe1, Daniel M Hinds1,2, Adrianne Colborg1,3

  • 1Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado, USA.

Pediatric Pulmonology
|September 24, 2020
PubMed

Insights

Oral antibiotic use for pediatric cystic fibrosis (CF) pulmonary exacerbations (PEx) is common, with over half prescribed via phone. Most children improved lung function, but hospitalizations occurred in 19%.

Area of Science:

  • Pediatric Pulmonology
  • Infectious Diseases
  • Pharmacology

Background:

  • Oral antibiotics are standard treatment for pediatric cystic fibrosis (CF) pulmonary exacerbations (PEx).
  • Understanding prescribing patterns and outcomes is crucial for optimizing care.

Purpose of the Study:

  • To characterize oral antibiotic use for PEx in children with CF.
  • To evaluate treatment outcomes based on care setting (clinic vs. phone).

Main Methods:

  • Retrospective, descriptive study of children aged 6-17 years with CF over one year.
  • Analysis of 763 oral antibiotic courses, noting prescription setting and antibiotic class.
  • Comparison of outcomes between clinic-initiated and phone-initiated prescriptions.

Main Results:

  • 58% of 763 oral antibiotic courses were prescribed over the phone.
  • Penicillin was the most frequent antibiotic class; prescribing varied between centers.
  • 87% of patients achieved FEV1 recovery to 90% of baseline within 6 months; 19% were hospitalized within 3 months.

Conclusions:

  • Phone prescriptions are a significant component of PEx management and should be included in studies.
  • Heterogeneity in antibiotic prescribing exists between CF centers.
  • While most patients show lung function improvement, hospitalizations remain a concern, highlighting the need to optimize telemedicine-based care.
Abstract

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
332
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
601
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
356
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
595
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
881